Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trabectedin - Johnson & Johnson/University of Illinois

Drug Profile

Trabectedin - Johnson & Johnson/University of Illinois

Alternative Names: Ecteinascidin; Ecteinascidin-743; ET-743; NSC-684766; Yondelis

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Illinois
  • Developer Bristol-Myers Squibb; European Organisation for Research and Treatment of Cancer; Johnson & Johnson; Mario Negri Institute for Pharmacological Research; National Cancer Institute (USA); PharmaMar; Taiho Pharmaceutical
  • Class Antineoplastics; Dioxoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Macrophage inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer; Soft tissue sarcoma
  • Phase III Fallopian tube cancer; Peritoneal cancer
  • Phase II Leiomyosarcoma; Liposarcoma; Malignant-mesothelioma; Meningioma; Non-small cell lung cancer; Solid tumours
  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Late-stage disease) in Japan (IV, Infusion)
  • 19 Dec 2023 National Center for Tumor Diseases, Heidelberg collaboration with AstraZeneca and PharmaMar completes a (phase) trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Germany (IV) (EudraCT2017-001755-31) (NCT03127215)
  • 16 Feb 2023 Registered for Soft tissue sarcoma (Late-stage disease, Second-line therapy or greater) in New Zealand (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top